 |
|
One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis
Ph. Gabriel Steg, MD;
Deepak L. Bhatt, MD;
Peter W. F. Wilson, MD;
Ralph D’Agostino, Sr, MD;
E. Magnus Ohman, MD;
Joachim Röther, MD;
Chiau-Suong Liau, MD, PhD;
Alan T. Hirsch, MD;
Jean-Louis Mas, MD;
Yasuo Ikeda, MD;
Michael J. Pencina, PhD;
Shinya Goto, MD; for the REACH Registry Investigators
JAMA. 2007;297:1197-1206.
Context Few data document current cardiovascular (CV) event rates in stable patients with atherothrombosis in a community setting. Differential event rates for patients with documented coronary artery disease (CAD), cerebrovascular disease (CVD), or peripheral arterial disease (PAD) or those at risk of these diseases have not been previously evaluated in a single international cohort.
Objective To establish contemporary, international, 1-year CV event rates in outpatients with established arterial disease or with multiple risk factors for atherothrombosis.
Design, Setting, and Participants The Reduction of Atherothrombosis for Continued Health (REACH) Registry is an international, prospective cohort of 68 236 patients with either established atherosclerotic arterial disease (CAD, PAD, CVD; n = 55 814) or at least 3 risk factors for atherothrombosis (n = 12 422), who were enrolled from 5587 physician practices in 44 countries in 2003-2004.
Main Outcome Measures Rates of CV death, myocardial infarction (MI), and stroke.
Results As of July 2006, 1-year outcomes were available for 95.22% (n = 64 977) of participants. Cardiovascular death, MI, or stroke rates were 4.24% overall: 4.69% for those with established atherosclerotic arterial disease vs 2.15% for patients with multiple risk factors only. Among patients with established disease, CV death, MI, or stroke rates were 4.52% for patients with CAD, 6.47% for patients with CVD, and 5.35% for patients with PAD. The incidences of the end point of CV death, MI, or stroke or of hospitalization for atherothrombotic event(s) were 15.20% for CAD, 14.53% for CVD, and 21.14% for PAD patients with established disease. These event rates increased with the number of symptomatic arterial disease locations, ranging from 5.31% for patients with risk factors only to 12.58% for patients with 1, 21.14% for patients with 2, and 26.27% for patients with 3 symptomatic arterial disease locations (P<.001 for trend).
Conclusions In this large, contemporary, international study, outpatients with established atherosclerotic arterial disease, or at risk of atherothrombosis, experienced relatively high annual CV event rates. Multiple disease locations increased the 1-year risk of CV events.
Author Affiliations: Département de Cardiologie, Hôpital Bichat-Claude Bernard, Paris, France (Dr Steg); Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio (Dr Bhatt); Cardiology Division, Emory University School of Medicine, Atlanta, Ga (Dr Wilson); Statistics and Consulting Unit, Department of Mathematics and Statistics, Boston University, Boston, Mass (Drs D’Agostino and Pencina); Division of Cardiology, Duke University, Durham, NC (Dr Ohman); Department of Neurology, Klinikum Minden, Minden, Germany (Dr Röther); Department of Internal Medicine, National Taiwan University Hospital and School of Medicine, Taipei, Taiwan (Dr Liau);Minneapolis Heart Institute Foundation and Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis (Dr Hirsch); Service de Neurologie, Centre Raymond Garcin, Hôpital Sainte-Anne, Paris, France (Dr Mas); Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan (Dr Ikeda); and Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan (Dr Goto).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
The International Pandemic of Chronic Cardiovascular Disease
Mary McGrae McDermott
JAMA. 2007;297(11):1253-1255.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Heart rate as a treatable cardiovascular risk factor
Tardif
Br Med Bull 2009;90:71-84.
ABSTRACT
| FULL TEXT
Continuously-Infused Human C-Reactive Protein Is Neither Proatherosclerotic Nor Proinflammatory in Apolipoprotein E-Deficient Mice
Ortiz et al.
Exp. Biol. Med. 2009;234:624-631.
ABSTRACT
| FULL TEXT
Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials
Berger et al.
JAMA 2009;301:1909-1919.
ABSTRACT
| FULL TEXT
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes
Bhatt et al.
Eur Heart J 2009;30:1195-1202.
ABSTRACT
| FULL TEXT
Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors
Collins et al.
Circulation 2009;119:922-930.
ABSTRACT
| FULL TEXT
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Kuliczkowski et al.
Eur Heart J 2009;30:426-435.
ABSTRACT
| FULL TEXT
The Essen Stroke Risk Score Predicts Recurrent Cardiovascular Events: A Validation Within the REduction of Atherothrombosis for Continued Health (REACH) Registry
Weimar et al.
Stroke 2009;40:350-354.
ABSTRACT
| FULL TEXT
Heart Disease and Stroke Statistics--2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
WRITING GROUP MEMBERS et al.
Circulation 2009;119:e21-e181.
FULL TEXT
Patients with peripheral arterial disease in the CHARISMA trial
Cacoub et al.
Eur Heart J 2009;0:ehn534v1-10.
ABSTRACT
| FULL TEXT
Amino-Terminal Pro-B-Type Natriuretic Peptide as Predictor of Mortality in Patients with Symptomatic Peripheral Arterial Disease: 5-Year Follow-Up Data from the Linz Peripheral Arterial Disease Study
Mueller et al.
Clin. Chem. 2009;55:68-77.
ABSTRACT
| FULL TEXT
Secondary Prevention of Atherothrombotic Events After Ischemic Stroke
Adams
Mayo Clin Proc. 2009;84:43-51.
ABSTRACT
| FULL TEXT
Current Status of Percutaneous Coronary Intervention With Drug-Eluting Stents in Asia
Park and Kim
Circulation 2008;118:2730-2737.
FULL TEXT
The challenge of monitoring platelet response after clopidogrel
Serebruany and Goto
Eur Heart J 2008;29:2833-2834.
FULL TEXT
Can Measuring the Ankle-Brachial Index Improve Public Health?
Hiatt
J Am Coll Cardiol 2008;52:1743-1744.
FULL TEXT
Long-Term Outcomes of Coronary-Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Multivessel Coronary Artery Disease in the Bare-Metal Stent Era
Kimura et al.
Circulation 2008;118:S199-S209.
ABSTRACT
| FULL TEXT
One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States
Mahoney et al.
Circ Cardiovasc Qual Outcomes 2008;1:38-45.
ABSTRACT
| FULL TEXT
Peripheral Arterial Disease: Diagnosis and Management
Arain and Cooper
Mayo Clin Proc. 2008;83:944-950.
ABSTRACT
| FULL TEXT
Management of Peripheral Arterial Disease
Steffen et al.
Diabetes Spectr. 2008;21:171-177.
ABSTRACT
| FULL TEXT
Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke prevention
Amarenco and Steg
Eur Heart J 2008;29:1605-1607.
FULL TEXT
Unmet needs in antiplatelet therapy
Bassand
Eur Heart J Suppl 2008;10:D3-D11.
ABSTRACT
| FULL TEXT
INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin?
BAKHRU and BHATT
Cleveland Clinic Journal of Medicine 2008;75:289-295.
ABSTRACT
| FULL TEXT
The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2008;51:944-955.
FULL TEXT
Elucidating the Genetic Basis of Peripheral Arterial Disease: Identification of a Quantitative Trait Locus That Determines the Phenotypic Response to Experimental Hindlimb Ischemia
Messina
Circulation 2008;117:1127-1129.
FULL TEXT
Oral Buflomedil in the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Obstructive Disease: A Randomized, Placebo-Controlled, 4-Year Study
Limbs International Medicinal Buflomedil (LIMB) St
Circulation 2008;117:816-822.
ABSTRACT
| FULL TEXT
Preoperative cardiac risk assessment in vascular surgery patients: seeing beyond the perioperative period
Schouten et al.
Eur Heart J 2008;29:283-284.
FULL TEXT
Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Writing Group Members et al.
Circulation 2008;117:e25-e146.
FULL TEXT
Peripheral arterial disease enters the biomarker era. Does risk stratification tell us something that we don't already know?
Gornik
Eur Heart J 2008;29:150-152.
FULL TEXT
Risk assessment in the patient with established peripheral arterial disease
Haugen et al.
Vasc Med 2007;12:343-350.
ABSTRACT
Response to Letter by Cote
Goessens et al.
Stroke 2007;38:e149-e149.
FULL TEXT
Gaps in Public Knowledge of Peripheral Arterial Disease: The First National PAD Public Awareness Survey
Hirsch et al.
Circulation 2007;116:2086-2094.
ABSTRACT
| FULL TEXT
The Year in Non ST-Segment Elevation Acute Coronary Syndrome
Giugliano and Braunwald
J Am Coll Cardiol 2007;50:1386-1395.
FULL TEXT
Peripheral arterial disease -- a cardiovascular time bomb
Belch et al.
British Journal of Diabetes & Vascular Disease 2007;7:236-239.
ABSTRACT
Overview of large morbidity/mortality trials with ivabradine: focus on the BEAUTIfUL study
Steg
Eur Heart J Suppl 2007;9:F15-F19.
ABSTRACT
| FULL TEXT
The International Pandemic of Chronic Cardiovascular Disease
McDermott
JAMA 2007;297:1253-1255.
FULL TEXT
|
